The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Guo, Yiru ^a   Tukaye, Deepali Nivas ^a   Wu, Wen Jian ^a   Zhu, Xiaoping ^a   Book, Michael ^a   Tan, Wei ^a   Jones, Steven P ^a   Rokosh, Gregg ^a   Narumiya, Shuh ^b   Li, Qianhong ^a   Bolli, Roberto ^a  

^a University of Louisville School of Medicine   (United States)

^b KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROSTACYCLIN; PROSTACYCLIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COX2 GENE; GENE; GENE DELETION; GENE FUNCTION; GENE INACTIVATION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; IN VIVO STUDY; IP GENE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN FUNCTION; RECEPTOR BLOCKING;

ANIMALS; BENZOFURANS; CYCLOOXYGENASE 2; GENE KNOCKOUT TECHNIQUES; HEART RATE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LIVER; MALE; MICE; MYOCARDIAL INFARCTION; MYOCARDIUM; PILOT PROJECTS; PROPIONATES; RECEPTORS, EPOPROSTENOL; TEMPERATURE; TIME FACTORS;

MUS;

EID: 84864206593     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041178     Document Type: Article

References (101)

1. Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, et al. (1998) Demonstration of an early and a late phase of ischemic preconditioning in mice. Am J Physiol 275: H1375-1387.
2. Ovize M, Kloner RA, Hale SL, Przyklenk K, (1992) Coronary cyclic flow variations "precondition" ischemic myocardium. Circulation 85: 779-789.
3. Bolli R, (1996) The early and late phases of preconditioning against myocardial stunning and the essential role of oxyradicals in the late phase: an overview. Basic Res Cardiol 91: 57-63.
4. Qiu Y, Tang XL, Park SW, Sun JZ, Kalya A, et al. (1997) The early and late phases of ischemic preconditioning: a comparative analysis of their effects on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40-minute coronary occlusion. Circ Res 80: 730-742.
5. Stein AB, Tang XL, Guo Y, Xuan YT, Dawn B, et al. (2004) Delayed adaptation of the heart to stress: late preconditioning. Stroke 35: 2676-2679.
6. Bolli R, Manchikalapudi S, Tang XL, Takano H, Qiu Y, et al. (1997) The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ Res 81: 1094-1107.
7. Bolli R, (2000) The late phase of preconditioning. Circ Res 87: 972-983.
8. Jones WK, Flaherty MP, Tang XL, Takano H, Qiu Y, et al. (1999) Ischemic preconditioning increases iNOS transcript levels in conscious rabbits via a nitric oxide-dependent mechanism. J Mol Cell Cardiol 31: 1469-1481.
9. Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, et al. (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A 96: 11507-11512.
10. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, et al. (2007) Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 116: 535-544.
11. West MB, Rokosh G, Obal D, Velayutham M, Xuan YT, et al. (2008) Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation 118: 1970-1978.
12. Wang Y, Guo Y, Zhang SX, Wu WJ, Wang J, et al. (2002) Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte. J Mol Cell Cardiol 34: 5-15.
13. Li Q, Guo Y, Wu WJ, Ou Q, Zhu X, et al. (2011) Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol 106: 1355-1366.
14. Li Q, Guo Y, Tan W, Stein AB, Dawn B, et al. (2006) Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol 290: H584-589.
15. Li Q, Guo Y, Tan W, Ou Q, Wu WJ, et al. (2007) Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway. Circulation 116: 1577-1584.
16. Li Q, Guo Y, Ou Q, Cui C, Wu WJ, et al. (2009) Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway. Circulation 120: 1222-1230.
17. Guo Y, Sanganalmath SK, Wu W, Zhu X, Huang Y, et al. (2012) Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury. Basic Res Cardiol 107: 253.
18. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, et al. (2004) IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 64: 61-71.
19. Heusch G, Boengler K, Schulz R, (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118: 1915-1919.
20. Benjamin IJ, Guo Y, Srinivasan S, Boudina S, Taylor RP, et al. (2007) CRYAB and HSPB2 deficiency alters cardiac metabolism and paradoxically confers protection against myocardial ischemia in aging mice. Am J Physiol Heart Circ Physiol 293: H3201-3209.
21. Yoshida K, Maaieh MM, Shipley JB, Doloresco M, Bernardo NL, et al. (1996) Monophosphoryl lipid A induces pharmacologic 'preconditioning' in rabbit hearts without concomitant expression of 70-kDa heat shock protein. Mol Cell Biochem 156: 1-8.
22. Qian YZ, Bernardo NL, Nayeem MA, Chelliah J, Kukreja RC, (1999) Induction of 72-kDa heat shock protein does not produce second window of ischemic preconditioning in rat heart. Am J Physiol 276: H224-234.
23. Amour J, Brzezinska AK, Weihrauch D, Billstrom AR, Zielonka J, et al. (2009) Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. Anesthesiology 110: 317-325.
24. Tang XL, Qiu Y, Turrens JF, Sun JZ, Bolli R, (1997) Late preconditioning against stunning is not mediated by increased antioxidant defenses in conscious pigs. Am J Physiol 273: H1651-1657.
25. Yamashita N, Hoshida S, Taniguchi N, Kuzuya T, Hori M, (1998) A "second window of protection" occurs 24 h after ischemic preconditioning in the rat heart. J Mol Cell Cardiol 30: 1181-1189.
26. Li Q, Bolli R, Qiu Y, Tang XL, Guo Y, et al. (2001) Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation 103: 1893-1898.
27. Li Q, Bolli R, Qiu Y, Tang XL, Murphree SS, et al. (1998) Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. Circulation 98: 1438-1448.
28. Shinmura K, Bolli R, Liu SQ, Tang XL, Kodani E, et al. (2002) Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res 91: 240-246.
29. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, et al. (2000) Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 97: 10197-10202.
30. Guo Y, Bao W, Wu WJ, Shinmura K, Tang XL, et al. (2000) Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res Cardiol 95: 479-484.
31. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, et al. (2005) Role of the protein kinase C-epsilon-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. Circulation 112: 1971-1978.
32. Xuan YT, Guo Y, Zhu Y, Han H, Langenbach R, et al. (2003) Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol 35: 525-537.
33. Wang Y, Kodani E, Wang J, Zhang SX, Takano H, et al. (2004) Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2. Circ Res 95: 84-91.
34. Stein AB, Bolli R, Dawn B, Sanganalmath SK, Zhu Y, et al. (2012) Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. J Mol Cell Cardiol 52: 228-236.
35. Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, et al. (2002) Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90: 602-608.
36. Shinmura K, Nagai M, Tamaki K, Tani M, Bolli R, (2002) COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts. Am J Physiol Heart Circ Physiol 283: H2534-2543.
37. Shinmura K, Nagai M, Tamaki K, Bolli R, (2004) Gender and aging do not impair opioid-induced late preconditioning in rats. Basic Res Cardiol 99: 46-55.
38. Shinmura K, Kodani E, Xuan YT, Dawn B, Tang XL, et al. (2003) Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. J Am Coll Cardiol 41: 1183-1194.
39. Sato H, Bolli R, Rokosh GD, Bi Q, Dai S, et al. (2007) The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats. Am J Physiol Heart Circ Physiol 293: H2557-2564.
40. Li Q, Guo Y, Xuan YT, Lowenstein CJ, Stevenson SC, et al. (2003) Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res 92: 741-748.
41. Kodani E, Xuan YT, Shinmura K, Takano H, Tang XL, et al. (2002) Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits. Am J Physiol Heart Circ Physiol 283: H1943-1957.
42. Bolli R, Stein AB, Guo Y, Wang OL, Rokosh G, et al. (2011) A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J Mol Cell Cardiol 50: 589-597.
43. Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, et al. (2002) Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55: 506-519.
44. Bolli R, Dawn B, Xuan YT, (2003) Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 13: 72-79.
45. Hu LF, Pan TT, Neo KL, Yong QC, Bian JS, (2008) Cyclooxygenase-2 mediates the delayed cardioprotection induced by hydrogen sulfide preconditioning in isolated rat cardiomyocytes. Pflugers Arch 455: 971-978.
46. Patel HH, Hsu AK, Gross GJ, (2004) COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat. Life Sci 75: 129-140.
47. Przyklenk K, Heusch G, (2003) Late preconditioning against myocardial stunning. Does aspirin close the "second window" of endogenous cardioprotection? J Am Coll Cardiol 41: 1195-1197.
48. Tanaka K, Ludwig LM, Krolikowski JG, Alcindor D, Pratt PF, et al. (2004) Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology 100: 525-531.
49. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC, (1999) Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 339 (Pt 3): 607-614.
50. Lin H, Lin TN, Cheung WM, Nian GM, Tseng PH, et al. (2002) Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 105: 1962-1969.
51. Xiao CY, Hara A, Yuhki K, Fujino T, Ma H, et al. (2001) Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104: 2210-2215.
52. Johnson G III, Furlan LE, Aoki N, Lefer AM, (1990) Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. Circ Res 66: 1362-1370.
53. Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, et al. (1978) Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200: 52-54.
54. Jugdutt BI, Hutchins GM, Bulkley BH, Becker LC, (1981) Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res 49: 685-700.
55. Jugdutt BI, Hutchins GM, Bulkley BH, Becker LC, (1980) Dissimilar effects of PGE1 and PGE2 on myocardial infarct size after coronary occlusion in conscious dogs. Adv Prostaglandin Thromboxane Res 7: 675-677.
56. Hong TT, Huang J, Barrett TD, Lucchesi BR, (2008) Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am J Physiol Heart Circ Physiol 294: H145-155.
57. Bley KR, Bhattacharya A, Daniels DV, Gever J, Jahangir A, et al. (2006) RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol 147: 335-345.
58. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, et al. (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482.
59. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, et al. (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388: 678-682.
60. Bolli R, (2001) Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33: 1897-1918.
61. Stein AB, Guo Y, Tan W, Wu WJ, Zhu X, et al. (2005) Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. J Mol Cell Cardiol 38: 127-134.
62. Guo Y, Stein AB, Wu WJ, Zhu X, Tan W, et al. (2005) Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS. Am J Physiol Heart Circ Physiol 289: H2251-2257.
63. Guo Y, Stein AB, Wu WJ, Tan W, Zhu X, et al. (2004) Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. Am J Physiol Heart Circ Physiol 286: H1649-1653.
64. Guo Y, Li Q, Wu WJ, Tan W, Zhu X, et al. (2008) Endothelial nitric oxide synthase is not necessary for the early phase of ischemic preconditioning in the mouse. J Mol Cell Cardiol 44: 496-501.
65. Guo Y, Bolli R, Bao W, Wu WJ, Black RG, et al. (2001) Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol 33: 825-830.
66. Guo Y, Tang XL, Bao W, Bolli R, (2000) Measuring Ischemic injury-How to produce infarction in the mouse in vivo. The ISHR Handbook of Experimental of Laboratory Procedures (H.E.L.P.) Available:http://www.ishrworld.org/.
67. Wang GW, Guo Y, Vondriska TM, Zhang J, Zhang S, et al. (2008) Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection. J Mol Cell Cardiol 44: 1016-1022.
68. Li Q, Guo Y, Ou Q, Wu WJ, Chen N, et al. (2011) Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol 106: 1367-1377.
69. Hu X, Dai S, Wu WJ, Tan W, Zhu X, et al. (2007) Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 116: 654-663.
70. Guo Y, Xuan YT, Wu WJ, Zhu X, Zhu Y, et al. (2002) Role of the JAK-STAT pathway and cyclooxygenase-2 in exercise-induced late preconditioning. Circulation 106: II-313 (1571).
71. Guo Y, Xuan YT, Wu WJ, Zhu X, Tan W, et al. (2003) Heme oxygenase-1 mediates three different types of late preconditioning. Circulation 108: IV-93 (435).
72. Guo Y, Xuan YT, Wu WJ, Li QH, Tang XL, et al. (2001) Nitric oxide plays a dual role in exercise-induced late preconditioning. Circulation 104: II-60 (288).
73. Guo Y, Wu WJ, Zhu XP, Li QH, Tang XL, et al. (2001) Exercise-induced late preconditioning is triggered by generation of nitric oxide. J Mol Cell Cardiol 33: A41.
74. Guo Y, Wu WJ, Zhu X, Tan W, Bolli R, (2003) The development of the early phase of ischemic preconditioning in mice is not strain dependent. J Mol Cell Cardiol 35: A47 (P110).
75. Guo Y, Bao W, Wu WJ, Tang XL, Bolli R, (1999) Nitric oxide donors induce late preconditioning against myocardial infarction in mice. J Mol Cell Cardiol 31: A11 (A-19).
76. Guo Y, Bao W, Tang XL, Wu WJ, Takano H, et al. (2000) Pharmacological preconditioning (PC) with adenosine A1 and opioid δ1 receptor agonists is iNOS-dependent. Circulation 102: II-121 (582).
77. Guo Y, Bao W, Tang XL, Wu WJ, Takano H, et al. (2000) Activation of adenosine A1 and δ1 opioid receptors induces late preconditioning in mice. J Mol Cell Cardiol 32: A51 (H-54).
78. Flaherty MP, Guo Y, Tiwari S, Rezazadeh A, Hunt G, et al. (2008) The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. J Mol Cell Cardiol 45: 735-741.
79. Dawn B, Guo Y, Rezazadeh A, Wang OL, Stein AB, et al. (2004) Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol 37: 51-61.
80. Black RG, Guo Y, Ge ZD, Murphree SS, Prabhu SD, et al. (2002) Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circ Res 91: 165-172.
81. Bolli R, Marban E, (1999) Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79: 609-634.
82. Baxter GF, (1997) Ischaemic preconditioning of myocardium. Ann Med 29: 345-352.
83. Gres P, Schulz R, Jansen J, Umschlag C, Heusch G, (2002) Involvement of endogenous prostaglandins in ischemic preconditioning in pigs. Cardiovasc Res 55: 626-632.
84. Bolli R, Dawn B, Xuan YT, (2001) Emerging role of the JAK-STAT pathway as a mechanism of protection against ischemia/reperfusion injury. J Mol Cell Cardiol 33: 1893-1896.
85. Angeloni C, Motori E, Fabbri D, Malaguti M, Leoncini E, et al. (2011) H2O2 preconditioning modulates phase II enzymes through p38 MAPK and PI3K/Akt activation. Am J Physiol Heart Circ Physiol 300: H2196-2205.
86. Hausenloy DJ, Yellon DM, (2010) The second window of preconditioning (SWOP) where are we now? Cardiovasc Drugs Ther 24: 235-254.
87. McGettigan P, Henry D, (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633-1644.
88. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R, (2006) Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 99: 132-140.
89. Krotz F, Schiele TM, Klauss V, Sohn HY, (2005) Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 42: 312-324.
90. Emery P, Moore A, Hawkey C, (2005) Increased risk of cardiovascular events with coxibs and NSAIDs. Lancet 365: 1538.
91. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, et al. (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364: 2021-2029.
92. Mukherjee D, Nissen SE, Topol EJ, (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959.
93. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528, 1522 p following 1528.
94. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, et al. (2007) Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357: 360-369.
95. Camitta MG, Gabel SA, Chulada P, Bradbury JA, Langenbach R, et al. (2001) Cyclooxygenase-1 and-2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 104: 2453-2458.
96. Heusch G, Musiolik J, Gedik N, Skyschally A, (2011) Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 109: 1302-1308.
97. Lo RK, Liu AM, Wise H, Wong YH, (2008) Prostacyclin receptor-induced STAT3 phosphorylation in human erythroleukemia cells is mediated via Galpha(s) and Galpha(16) hybrid signaling. Cell Signal 20: 2095-2106.
98. Woodward DF, Jones RL, Narumiya S, (2010) International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 63: 471-538.
99. Wilson SJ, Dowling JK, Zhao L, Carnish E, Smyth EM, (2007) Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells: role of receptor heterodimerization. Arterioscler Thromb Vasc Biol 27: 290-296.
100. Ruan CH, Wu J, Ruan KH, (2005) A strategy using NMR peptide structures of thromboxane A2 receptor as templates to construct ligand-recognition pocket of prostacyclin receptor. BMC Biochem 6: 23.
101. Stitham J, Arehart E, Gleim SR, Li N, Douville K, et al. (2007) New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues. Br J Pharmacol 152: 513-522.